Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC.
Camille GauvinVimal KrishnanImane KaciDanh Tran-ThanhKarine BédardRoula AlbadineCharles LeducLouis Arthur GabouryNormand BlaisMustapha TehfeBertrand RoutyMarie FlorescuPublished in: Current oncology (Toronto, Ont.) (2021)
Aggressive treatments of oligometastatic NSCLC significantly improve mOS and mPFS compared to a more palliative approach. PD-L1 expression is a negative prognostic factor which suggests a possible role for immunotherapy in this setting.